Compare GKOS & DSGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | DSGX |
|---|---|---|
| Founded | 1998 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.2B |
| IPO Year | 2015 | 1999 |
| Metric | GKOS | DSGX |
|---|---|---|
| Price | $100.96 | $72.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $133.07 | $107.13 |
| AVG Volume (30 Days) | 577.7K | ★ 657.2K |
| Earning Date | 04-29-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $23.34 | $11.37 |
| Revenue Next Year | $27.46 | N/A |
| P/E Ratio | ★ N/A | $37.05 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $62.56 |
| 52 Week High | $130.23 | $117.35 |
| Indicator | GKOS | DSGX |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 55.02 |
| Support Level | $94.92 | $62.63 |
| Resistance Level | $104.66 | $74.73 |
| Average True Range (ATR) | 4.02 | 2.48 |
| MACD | -0.71 | 0.69 |
| Stochastic Oscillator | 22.45 | 76.65 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.